CVD Clinical Trial
— AIVARIXOfficial title:
A Study to Evaluate a Accuracy of the AIVARIX AI-based Application in Detecting Signs C 1-2 Classes of CVD in Outpatients Seeking Consultancy of Phlebologists in the Russian Federation
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Status | Not yet recruiting |
Enrollment | 414 |
Est. completion date | September 1, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age over 18 years - Written informed consent is provided - Symptoms and signs of CVD or any other skin pathologic condition (s) of lower extremities for which a patient seeks for phlebologist's consultation - Ability to fulfil the technical requirements for smartphones/ images Exclusion Criteria: - Patients with mental/ psychiatric disabilities who are not able to understand objectives of the study and therefore provide a signed consent to participate in the study. - Patient's decision to withdraw his/her consent to participate in the study at any moment of the study conduction |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Pirogov Russian National Research Medical University | Moscow |
Lead Sponsor | Collaborator |
---|---|
Servier Russia |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Sensitivity (Sn) of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD. | Sensitivity is defined as the ratio of the number of positive cases of detection of signs of C1 or C2 CVD, identified using the AIVARIX tool, to the total number of truly positive cases of C1 or C2 CVD in the study population, confirmed by phlebologists using objective / instrumental examinations. | 1 month | |
Primary | Evaluation of Specificity (Sp) of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD | Specificity is defined as a proportion of the number of negative cases of signs C1 or C2 classes of CVD identified by the AIVARIX tool divided to overall truly negative cases of C1 or C2 in the study population confirmed by phlebologists by means of objective/ instrumental examination. | 1 month | |
Secondary | Calculation of the positive predictive values (PPV) a of AIVARIX in detecting signs of C1 and C2 classes of chronic venous disease. | PPV is defined as the proportion of true positive cases of class C1 or C2 CVD detected using AIVARIX as a proportion of the number of true positive and false positive cases of class C 1 or C 2 identified using the AIVARIX application and confirmed by phlebologists. | 1 month | |
Secondary | Calculation of the negative predictive values (PPV) a of AIVARIX in detecting signs of C1 and C2 classes of chronic venous disease. | The NPV is defined as the ratio of the number of true negative cases of C 1 or C 2 CVD detected using AIVARIX to the true negative and false negative cases of C 1 or C 2 CVD detected using AIVARIX and confirmed by phlebologists. | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Active, not recruiting |
NCT00038727 -
Diabetes Prevention Program Outcomes Study
|
Phase 3 | |
Completed |
NCT03967678 -
Omega (n)-3 PUFA Enriched Beef & Health Outcomes.
|
N/A | |
Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
Not yet recruiting |
NCT05716659 -
EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
|
||
Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
Completed |
NCT01077388 -
e-Care for Heart Wellness
|
Phase 3 | |
Completed |
NCT04384029 -
The Geneva Covid-19 CVD Study
|
||
Active, not recruiting |
NCT02382822 -
Copenhagen Co-morbidity in HIV Infection Study
|
||
Active, not recruiting |
NCT01825668 -
Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy
|
N/A | |
Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
Completed |
NCT00289237 -
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
Completed |
NCT03636529 -
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
|
N/A | |
Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|
||
Completed |
NCT00500708 -
Diagnostic Investigation of Sudden Cardiac Event Risk
|
N/A | |
Completed |
NCT01255852 -
Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
|
Phase 4 | |
Completed |
NCT00583297 -
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
|
N/A |